ResMed Inc. (NYSE:RMD) Position Increased by MassMutual Private Wealth & Trust FSB

MassMutual Private Wealth & Trust FSB boosted its stake in ResMed Inc. (NYSE:RMD - Free Report) by 3.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 68,739 shares of the medical equipment provider's stock after acquiring an additional 2,142 shares during the quarter. MassMutual Private Wealth & Trust FSB's holdings in ResMed were worth $15,387,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Colonial Trust Co SC grew its holdings in ResMed by 6,250.0% during the 4th quarter. Colonial Trust Co SC now owns 127 shares of the medical equipment provider's stock valued at $29,000 after purchasing an additional 125 shares in the last quarter. Optiver Holding B.V. purchased a new position in ResMed in the 4th quarter valued at about $33,000. Itau Unibanco Holding S.A. grew its stake in shares of ResMed by 1,000.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 165 shares of the medical equipment provider's stock valued at $38,000 after acquiring an additional 150 shares in the last quarter. OFI Invest Asset Management acquired a new stake in shares of ResMed during the fourth quarter valued at about $39,000. Finally, Coppell Advisory Solutions LLC increased its position in shares of ResMed by 1,750.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 185 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 175 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company's stock.

ResMed Stock Performance

ResMed stock traded down $0.50 during midday trading on Friday, reaching $244.62. 1,060,298 shares of the stock traded hands, compared to its average volume of 1,024,582. The firm has a fifty day moving average price of $230.20 and a two-hundred day moving average price of $234.21. ResMed Inc. has a fifty-two week low of $179.42 and a fifty-two week high of $263.05. The firm has a market cap of $35.87 billion, a price-to-earnings ratio of 28.88, a PEG ratio of 1.53 and a beta of 0.78. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13.

ResMed (NYSE:RMD - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share for the quarter, beating the consensus estimate of $2.36 by $0.01. The firm had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.28 billion. ResMed had a return on equity of 26.17% and a net margin of 25.34%. The firm's revenue for the quarter was up 7.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.13 EPS. On average, equities research analysts forecast that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 12th. Investors of record on Thursday, May 8th will be given a $0.53 dividend. The ex-dividend date is Thursday, May 8th. This represents a $2.12 dividend on an annualized basis and a yield of 0.87%. ResMed's dividend payout ratio is presently 23.79%.

Analysts Set New Price Targets

A number of brokerages recently commented on RMD. UBS Group reduced their price target on ResMed from $290.00 to $285.00 and set a "buy" rating for the company in a report on Thursday, April 24th. KeyCorp set a $274.00 target price on ResMed in a research note on Thursday, April 24th. Stifel Nicolaus decreased their price target on shares of ResMed from $250.00 to $240.00 and set a "hold" rating for the company in a research report on Wednesday, March 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of ResMed in a report on Friday, January 31st. Finally, Wall Street Zen downgraded shares of ResMed from a "buy" rating to a "hold" rating in a research note on Saturday, May 24th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $259.33.

Insider Buying and Selling at ResMed

In other ResMed news, CEO Michael J. Farrell sold 8,009 shares of the business's stock in a transaction dated Monday, April 7th. The shares were sold at an average price of $209.85, for a total value of $1,680,688.65. Following the sale, the chief executive officer now directly owns 455,472 shares in the company, valued at approximately $95,580,799.20. The trade was a 1.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Witte Jan De sold 2,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $243.47, for a total transaction of $486,940.00. Following the sale, the director now owns 5,806 shares of the company's stock, valued at $1,413,586.82. The trade was a 25.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,949 shares of company stock valued at $11,822,260. Company insiders own 0.71% of the company's stock.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.